drugset / Trial / NCT05739045
Nivolumab Combined With SOX Used in the Perioperative Treatment
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma;
Timeline
- Start
- 2022-11-03
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | S-1 | Small molecule | — | — |